Furthermore, we found that lenvatinib could increase AZGP1 expression by increasing the acetylation level of H3K27Ac in the promoter region of the AZGP1 gene, thereby inhibiting EMT in ICC cells. The gene discussed is AZGP1; the disease is intrahepatic cholangiocarcinoma.